BIOMAT Database Logo BIOMAT Database Logo

Combined radiotherapy and Corynebacterium parvum treatment of rat tumors with different immunogenicity. 1978

H Moroson, and S Stowe, and M Rotman, and M Schechter

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008325 Mammary Neoplasms, Experimental Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS. Experimental Mammary Neoplasms,Neoplasms, Experimental Mammary,Experimental Mammary Neoplasm,Mammary Neoplasm, Experimental,Neoplasm, Experimental Mammary
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D011425 Propionibacterium acnes A bacteria isolated from normal skin, intestinal contents, wounds, blood, pus, and soft tissue abscesses. It is a common contaminant of clinical specimens, presumably from the skin of patients or attendants. Corynebacterium acnes,Corynebacterium parvum
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005354 Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed) Fibrosarcomas
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000912 Antibodies, Neoplasm Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS. Neoplasm Antibodies,Tumor Antibodies,Antibodies, Tumor

Related Publications

H Moroson, and S Stowe, and M Rotman, and M Schechter
Combined radiotherapy and Corynebacterium parvum treatment of a murine fibrosarcoma.
October 1977, Radiology,
H Moroson, and S Stowe, and M Rotman, and M Schechter
Intralesional immunotherapy of brain tumors with combined Corynebacterium parvum and recombinant interleukin-2 in mice.
August 1990, Journal of the National Cancer Institute,
H Moroson, and S Stowe, and M Rotman, and M Schechter
Radiation therapy and Corynebacterium parvum in the treatment of murine tumors.
June 1976, Cancer,
H Moroson, and S Stowe, and M Rotman, and M Schechter
Treatment of an intracerebral rat brain tumor with Corynebacterium parvum and radiation.
December 1977, National Cancer Institute monograph,
H Moroson, and S Stowe, and M Rotman, and M Schechter
Proceedings: Combined surgery and Corynebacterium parvum for treatment of metastasizing tumour in mice.
February 1975, The British journal of surgery,
H Moroson, and S Stowe, and M Rotman, and M Schechter
Phase I study of corynebacterium parvum in patients with solid tumors.
January 1975, Cancer chemotherapy reports,
H Moroson, and S Stowe, and M Rotman, and M Schechter
Treatment of malignant ascitic and pleural effusion with Corynebacterium parvum.
February 1978, British medical journal,
H Moroson, and S Stowe, and M Rotman, and M Schechter
Treatment of malignant pleural effusions with intracavitary Corynebacterium parvum.
August 1988, Cancer,
H Moroson, and S Stowe, and M Rotman, and M Schechter
Inhibition of hepatic drug metabolism in the rat after Corynebacterium parvum treatment.
April 1983, Biochemical pharmacology,
H Moroson, and S Stowe, and M Rotman, and M Schechter
Clinical studies with Corynebacterium parvum.
January 1977, Developments in biological standardization,
Copied contents to your clipboard!